Aspectos fisiopatológicos y manifestaciones neurológicas asociadas a la infección por SARSCoV-2/COVID-19.

Pathophysiologic aspects and neurological manifestations associated with SARS-CoV-2 infection/COVID-19.

Contenido principal del artículo

José de Jesús Bohórquez Rivero
José David Sáenz López
Keyner Enrique Tatis Villamizar
Roberto Carlos Guzmán Sáenz

Resumen

Introducción: el SARS-CoV-2 representa al patógeno causante de la enfermedad denominada COVID-19. Dicha patología se ha extendido rápidamente a nivel mundial, constituyendo un importante problema de salud pública. Sus características clínicas no se limitan al tracto respiratorio, sino que también comprometen al sistema nervioso. Objetivo: identificar los posibles mecanismos directos e indirectos por los cuales el SARS-CoV-2 afecta al sistema nervioso y describir los eventos fisiopatológicos responsables de las manifestaciones y complicaciones neurológicas reportadas en COVID-19. Métodos: se realizó una revisión narrativa de la literatura encontrada en las bases de datos PubMed y Science Direct y en el motor de búsqueda Google Scholar utilizando las palabras claves. Se incluyeron artículos en idioma español e inglés publicados en el año 2020. Resultados: se identificaron los posibles mecanismos de invasión directa del SARSCoV-2 al SNC (por las propiedades neurotrópicas del virus) y los mecanismos indirectos (derivados de las alteraciones metabólicas, el estado proinflamatorio y la desregulación del sistema inmune) detrás del compromiso neurológico asociado a COVID-19. Conclusiones: la identificación de los posibles mecanismos que explican como el SARS-CoV-2 ingresa, se establece en el SNC y lo afecta directamente, así como su afectación indirecta, son un pilar fundamental para la comprensión de los eventos fisiopatológicos que explican las manifestaciones clínicas y complicaciones neurológicas reportadas en COVID-19.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a (VER)

José de Jesús Bohórquez Rivero, Universidad del Sinú

Grupo de Investigación GIBACUS. Escuela de Medicina. Universidad del Sinú, Cartagena, Colombia.

José David Sáenz López, Universidad del Sinú

Grupo de Investigación GIBACUS. Escuela de Medicina. Universidad del Sinú, Cartagena, Colombia.

Keyner Enrique Tatis Villamizar, Universidad del Sinú

Grupo de Investigación GIBACUS. Escuela de Medicina. Universidad del Sinú, Cartagena, Colombia

Roberto Carlos Guzmán Sáenz, Universidad del Norte

Departamento de Medicina Interna. Universidad del Norte. Barranquilla, Colombia

Palabras clave:

Referencias (VER)

1. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020; doi: 10.1038/s41582-020-0398-3

2. Vergara JP, Tolosa C. Covid 19: manifestaciones neurológicas. Acta Neurol Colomb. 2020; vol.36, suppl.1, pp.7-10. ISSN 0120-8748. doi:10.22379/24224022288

3. Tsivgoulis G, Palaiodimou L, Katsanos AH, Caso V, Köhrmann M, Molina C, et al. Neurological manifestations and implications of COVID-19 pandemic. Ther Adv Neurol Disord. 2020; 13:1756286420932036. doi: 10.1177/1756286420932036

4. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265-269. doi: 10.1038/s41586-020-2008-3

5. DosSantos MF, Devalle S, Aran V, Capra D, Roque NR, Coelho-Aguiar JM, et al. Neuromechanisms of SARS-CoV-2: A Review. Front Neuroanat. 2020; 14(37): 1-12. DOI: 10.3389/fnana.2020.00037

6. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; doi: 10.1161/CIRCRESAHA

7. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020; 11(7): 995-998. doi: 10.1021/acschemneuro.0c00122

8. Pennisi M, Lanza G, Luca Falzone, Fisicaro F, Ferri R, Bella R. SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms. Int J Mol Sci. 2020; 21(15): 5475. DOI: 10.3390/ijms21155475

9. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clinical Neurology and Neurosurgery. 2020; 194, 105921. doi: 10.1016/j.clineuro.2020.105921

10. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020; 6(31): eabc5801. doi: 10.1126/sciadv.abc5801

11. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020; 94: 55-58. doi: 10.1016/j.ijid.2020.03.062

12. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020; 13(5): 667-673. doi: 10.1016/j.jiph.2020.03.019

13. Abuabara E, Bohórquez J, Restom J, Sáenz J, Correa J, Mendoza C. Consideraciones actuales de antimaláricos en la infección por SARS-CoV-2 y su impacto. Rev. Colomb. Nefrol. 2020; doi: 10.22265/acnef.7.Supl%202.406

14. Sachdev K, Agrawal S, Ish P, Gupta N, Raheja K. Neurological manifestations of COVID-19: A brief review. Indian J Med Res. 2020; (1&2): 41-47. doi: 10.4103/ijmr.IJMR_1395_20

15. Carod-Artal FJ. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol 2020; 70 (09): 311-322 doi: 10.33588/rn.7009.2020179

16. Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. Neurocrit Care. 2020; doi: 10.1007/s12028-020-01049-4

17. Abduljalil JM, Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New Microbes New Infect. 2020; 35: 100672. doi: 10.1016/j.nmni.2020.100672

18. Deng YY, Zheng Y, Cai GY, Chen XM, Hong Q. Single-cell RNA sequencing data suggest a role for angiotensin-converting enzyme 2 in kidney impairment in patients infected with 2019-novel coronavirus. Chin Med J. 2020; 133(9): 1129-1131. doi: 10.1097/CM9.0000000000000783

19. Conde Cardona G, Quintana Pájaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR. Neurotropism of SARS-CoV 2: Mechanisms and manifestations. J Neurol Sci. 2020; 412: 116824. doi: 10.1016/j.jns.2020.116824

20. Moreno Zambrano D, Arévalo Mora M , Freire Bonifacini A, García Santibáñez R, Santibáñez Vásquez R. Manifestaciones Neurológicas Asociadas a la Infección Por SARS-CoV-2: Una Neuro-Revisión de COVID-19. Rev Ecuat Neurol. 2020; 29 (1): 115-124.

21. Orozco-Hernández JP, Marin-Medina DS, Sánchez-Duque JA. Manifestaciones neurológicas de la infección por SARS-CoV-2 [Neurological manifestations of SARS-CoV-2 infection]. Semergen. 2020; S1138-3593(20)30143-X. doi: 10.1016/j.semerg.2020.05.004

22. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020. doi:10.1002/jmv.25728

23. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir. 2020; 162(7): 1491-1494. doi:10.1007/s00701-020-04374-x

24. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 13; 7(1): 11. doi: 10.1186/s40779-020-00240-0

25. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; (5): 475-481. doi: 10.1016/S2213-2600(20)30079-5

26. Karimi N, Sharifi Razavi A, Rouhani N. Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report, Iran Red Crescent Med J. 2020; 22(3): e102828. doi: 10.5812/ircmj.102828

27. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020; 945-946. doi: 10.1016/j.bbi.2020.04.017

28. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 1033-1034. doi: 10.1016/S0140-6736(20)30628-0

29. Huang J, Zheng M, Tang X, Chen Y, Tong A, Zhou L. Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience. Front Neurol. 2020; 11: 659. doi: 10.3389/fneur.2020.00659

30. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss in the era of COVID-19. Int Forum Allergy Rhinol. 2020; 10(7): 814-820. doi: 10.1002/alr.22578

31. Vaira LA, Salzano G, Fois AG, Piombino P, De Riu G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy Rhinol. 2020; 10(9): 1103-1104. doi: 10.1002/alr.22593

32. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020; 296(2): E119-E120. doi: 10.1148/radiol.2020201187

33. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 1-9. doi: 10.1001/jamaneurol.2020.1127

34. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020; 382(23): 2268-2270. doi:10.1056/NEJMc2008597

35. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020; 77: 8-12. DOI: 10.1016/j.jocn.2020.05.017

36. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J. 2020; 133(11): 1261-1267. doi: 10.1097/CM9.0000000000000824

37. Filatov A, Sharma P, Hindi F, et al. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020; 12(3): e7352. doi: 10.7759/cureus.7352

38. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091. doi: 10.1136/bmj.m1091

39. Jasti M, Nalleballe K, Dandu V, Onteddu S. A review of pathophysiology and neuropsychiatric manifestations of COVID-19. J Neurol. 2020; 1-6. doi: 10.1007/s00415-020-09950-w

40. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurology. 2020; 19(9): 767–783. doi: 10.1016/S1474-4422(20)30221-0

41. Saleki K, Banazadeh M, Saghazadeh A, Rezaei N. The involvement of the central nervous system in patients with COVID-19. Rev Neurosci. 2020; 31(4): 453-456. doi: 10.1515/revneuro-2020-0026

42. Sotoca J, Rodríguez-Álvarez J. COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (5) e803; doi: 10.1212/NXI.0000000000000803

43. Durrani M, Kucharski K, Smith Z, Fien S. Acute Transverse Myelitis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Case Report. Clin Pract Cases Emerg Med. 2020; 4(3): 344-348. doi: 10.5811/cpcem.2020.6.48462

44. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol. 2020; doi: 10.1016/S1474-4422(20)30109-5

45. AlKetbi R, AlNuaimi D, AlMulla M, et al. Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings. Radiol Case Rep. 2020; 15(9): 1591-1595. Published 2020 Jun 6. doi: 10.1016/j.radcr.2020.06.001

46. Sarma D, Bilello LA. A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection. Clin Pract Cases Emerg Med. 2020; 4(3): 321-323. doi:10.5811/cpcem.2020.5.47937

47. Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental?. New Microbes New Infect. 2020; 35: 100669. doi: 10.1016/j.nmni.2020.100669

48. Fan H, Tang X, Song Y, Liu P, Chen Y. Influence of COVID-19 on Cerebrovascular Disease and its Possible Mechanism. Neuropsychiatr Dis Treat. 2020; 16: 1359-1367. doi: 10.2147/NDT.S251173

49. Sharifian-Dorche M, Huot P, Osherov M, Wen D, Saveriano A, Giacomini PS, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020. 15; 417: 117085. doi: 10.1016/j.jns.2020.117085

50. Trejos-Gabriel JM. Stroke as a complication and prognostic factor of COVID-19. Neurologia. 2020; 35(5): 318-322. doi: 10.1016/j.nrl.2020.04.01529

51. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020; 10(7): 806-813. doi: 10.1002/alr.22579

52. Bagheri SH, Asghari A, Farhadi M, Shamshiri AR, Kabir A, Kamrava SK, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islam Repub Iran. 2020; doi: 10.34171/mjiri.34.62

53. Redondo-Urda MJ, Rodríguez-Peguero FJ, Pérez-Gil O, Del Valle-Sánchez M, Carrera-Izquierdo M. SARS-CoV-2, nuevo agente causal del síndrome de Guillain-Barré [SARS-CoV-2, a new causal agent of Guillain-Barre syndrome]. Rev Neurol. 2020; 71(7): 275-276. doi: 10.33588/rn.7107.2020264

54. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. ID Cases. 2020; 20: e00771. doi: 10.1016/j.idcr.2020.e00771

55. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020 Jun; 76: 233-235. doi: 10.1016/j.jocn.2020.04.062

56. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020; doi: 10.1056/NEJMc2009191

57. Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020; 26(7): 10.3201/eid2607.200445. doi:10.3201/eid2607.200445

58. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020; doi: 10.1212/WNL.0000000000009619

59. Wan Y, Cao S, Fang Q, Wang M, Huang Y. Coronavirus disease 2019 complicated with Bell’s palsy: a case report. Research Square. 2020. DOI: 10.21203/rs.3.rs-23216/v1

60. Rahman MM, Azam MG, Bohorquez-Rivero J, Garcia-Ballestas E, Agrawal, Moscote-Salazar LR. Telehealth and telemedicine in the COVID-19 era: a world of opportunities for the neurosurgeons. World Neurosurg. 2020; doi: 10.1016/j.wneu.2020.06.064

61. Lyden P. AHA/ASA Stroke Council Leadership. Temporary emergency guidance to US stroke centers during the COVID-19 pandemic on behalf of the AHA/ASA stroke council leadership. Stroke. 2020; doi: 10.1161/STROKEAHA.120.030023

62. Khosravani H, Rajendram P, Notario L, Chapman MG, Menon BK. Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic. Stroke. 2020; doi: 10.1161/STROKEAHA.120.029838

Contadores